Viral Infections in Immunocompromised Hosts

Intro: IC Viral Infections - The Ground Rules

• Core issue: Impaired Cell-Mediated Immunity (CMI) is the primary defect.
• Impact: Leads to ↑ susceptibility, ↑ severity, prolonged duration, and atypical clinical presentations.
• Common pattern: Reactivation of latent viruses (e.g., HSV, VZV, CMV) is frequent.
• New infections: Can also be unusually severe and disseminated.
• Diagnostic challenge: Atypical lesions often necessitate skin biopsy for confirmation.
• Management principles: Higher antiviral doses, longer treatment courses; be alert for drug resistance. Prophylaxis is key in select groups.

⭐ Viral infections in IC hosts often manifest with unusually large, numerous, persistent, ulcerative, or even necrotic skin lesions.

Herpesviruses (HSV & VZV) - Fiery Foes

• Opportunistic infections in IC hosts; atypical presentations common.
• HSV (Herpes Simplex Virus):
  • Chronic, ulcerative, hypertrophic, or verrucous lesions common.
  • Dissemination risk: hepatitis, pneumonitis, encephalitis.
  • Dx: PCR (gold standard), Tzanck smear (multinucleated giant cells).
  • Tx: Acyclovir (high-dose). Resistance: Foscarnet, Cidofovir.
• VZV (Varicella-Zoster Virus):
  • Zoster: ↑ severity, duration, pain; ↑ risk of dissemination (cutaneous/visceral).
  • Chronic VZV: persistent, hyperkeratotic lesions.
  • ↑ risk/severity of Post-Herpetic Neuralgia (PHN).
  • Tx: Valacyclovir, Famciclovir. IV Acyclovir for severe/disseminated cases.

⭐ Hutchinson's sign (vesicles on tip/side/root of nose) in Herpes Zoster Ophthalmicus indicates nasociliary (V1) involvement, high risk of ocular complications.

Poxviruses & HPV - Persistent Pests

• Molluscum Contagiosum (MC) in Immunocompromised:
  • Manifestations: Numerous, large (>1 cm, giant), atypical (e.g., crusted, verrucous), persistent lesions.
  • Common sites: Face, neck, intertriginous, anogenital.
  • Indicator: Often reflects severe immunosuppression (e.g., HIV with CD4 < 100 cells/µL).
  • Management: HAART in HIV is primary. Destructive (cryo, curettage), topical (cidofovir, imiquimod).
  • 
• Human Papillomavirus (HPV) in Immunocompromised:
  • Manifestations: Extensive, recalcitrant warts (common, plantar, flat, anogenital).
  • Increased risk: Dysplasia and squamous cell carcinoma (SCC), especially with high-risk types (16, 18, 31, 33).
  • Management: Difficult due to high recurrence. Destructive methods, topical (imiquimod, 5-FU), intralesional cidofovir. Regular screening for malignancy.

⭐ In transplant recipients, HPV-associated SCCs are more frequent, aggressive, and often multiple.

CMV & HHV-8 (Kaposi's) - Deeper Threats

• Cytomegalovirus (CMV):
  • Reactivates in immunosuppression (AIDS CD4 < 50/µL, transplant).
  • Sites: Retina ("pizza-pie" fundoscopy), GI (colitis, esophagitis), pneumonitis.
  • Dx: PCR, biopsy ("owl's eye" inclusions).
  • Rx: Ganciclovir, Valganciclovir, Foscarnet.
• Human Herpesvirus-8 (HHV-8) / Kaposi's Sarcoma (KS):
  • HHV-8 driven angioproliferative malignancy, common in AIDS.
  • Clinical: Violaceous/brownish patches, plaques, nodules (skin, oral mucosa). May involve GI, lungs.
  • Dx: Biopsy (spindle cells, neovascularization).
  • Rx: HAART (AIDS-KS); local (cryo, intralesional chemo); systemic chemo for advanced disease.

⭐ Kaposi's Sarcoma is the most common malignancy in untreated AIDS patients; HAART often induces regression.

High‑Yield Points - ⚡ Biggest Takeaways

• Herpesviruses (HSV, VZV, CMV) cause severe, disseminated, or chronic infections.
• Atypical clinical presentations are frequent, often delaying diagnosis.
• CMV commonly affects retina, GIT, and lungs, especially in AIDS/transplant patients.
• Molluscum contagiosum can be giant, numerous, or widespread, particularly in HIV.
• HPV infections: extensive warts and ↑ risk of malignancy.
• Early diagnosis, aggressive antiviral therapy, and prophylaxis are critical.
• Watch for antiviral drug resistance (e.g., acyclovir-resistant HSV).